Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON48375
NL-OMON48375
Completed
Not Applicable

Whole blood thrombin generation, platelet activation test and platelet-monocyte complex formation to predict hypercoagulability in patients with multiple myeloma - Whole blood thrombin generation in patients with multiple myeloma

Synapse Research Institute0 sites42 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionscancer of plasma cellsPlasma cell myeloma10018865

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
cancer of plasma cells
Sponsor
Synapse Research Institute
Enrollment
42
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

Trial ended prematurely

Registry
who.int
Start Date
TBD
End Date
March 11, 2020
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Synapse Research Institute

Eligibility Criteria

Inclusion Criteria

  • •For all participants (patients and controls):
  • •\- Subjects of both gender
  • •\- Age \*18
  • •\- Written informed consent from the subject
  • •Patients with Multiple Myeloma:
  • •\- Stable condition
  • •\- Diagnosis of Multiple Myeloma
  • •\- On active treatment with IMiD
  • •\- Patient of the Meander Medical Center

Exclusion Criteria

  • •For all participants (patients and controls):
  • •\- Age below 18
  • •\- Known abnormalities of the coagulation system
  • •\- Pregnancy
  • •\- The use of anti\-coagulant drugs (low molecular weight heparin (LMWH), vitamin
  • •K antagonists (VKAs) and direct oral anticoagulants (DOACs))
  • •\- Active infection, bleeding or other systemic diseases
  • •For controls (relatives: family or no\-family):
  • •\- Active malignancy
  • •\- Personal history of bleeding or thrombotic events

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Plasmin generation in tPA-mediated fibrinolysis in patients with strokeCVAstroke1000318410014523
NL-OMON46577Gelre Ziekenhuizen8
Completed
Phase 3
A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable, Stage IIIB to IVM1c Melanoma (MASTERKEY-265)1) Unresectable stage IIIB to IVM1c melanoma2) Unremoved melanoma (type of skin cancer)10040900
NL-OMON50729Amgen15
Completed
Not Applicable
First in Human Study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PPSGG (PN-1007) in anti-MAG neuropathy patients.anti-MAG neuropathyauto-immune10012303
NL-OMON49059Polyneuron Pharmaceuticals AG9
Completed
Not Applicable
Verification of preoperative screening for bleeding tendency in patients that report bleeding symptomshemorrhagic diathesisbleeding tendency100644771000533010047075
NL-OMON40106niversiteit Maastricht439
Completed
Not Applicable
A first-in-human, randomized, subject-blinded, placebocontrolled, single ascending dose study to investigate the safety, tolerability and pharmacokinetics of MHS552 in healthy volunteers
NL-OMON49201ovartis64